A

Abbott

Global healthcare company manufacturing medical devices

Clinical Specialist 1

Full-TimeUpdated on 10/4/2026
$61.3k - $122.7k
Junior
Bachelor's
Phoenix, AZ, USA
RemoteTravel within or outside the assigned region is required 25% of the time.

About the job

Requirements
  • A bachelor's degree in biomedical engineering or a related field, or an equivalent combination of education and work experience.
  • One to two years of work experience; experience collaborating with patients in a clinical setting is strongly preferred.
  • Ability to communicate, understand, and educate others about clinical data in the Chronic Pain Therapies space.
  • Strong clinical skills.
  • Ability to work an unpredictable schedule that may occasionally change on short notice due to operating room schedule changes or delays.
  • Ability to work within a team and as an individual contributor in a fast-paced, changing environment.
  • Ability to work in a highly matrixed and geographically diverse business environment.
Responsibilities
  • Provide technical, clinical, and programming assistance, primarily in support of one or two Territory Managers.
  • Assist Territory Managers with after-hours call support and activities.
  • Integrate into accounts, build trust and relationships, and establish rapport with customers.
  • Provide complex programming and case support.
  • Work seamlessly with Territory Managers to increase their selling time.
  • Conduct PCP work and educational in-services as directed.
  • Contact, visit, and engage clients and potential clients in the Company's products, and address client questions and concerns as directed by the sales manager.
  • Provide medical professionals with sales support, product information, and training, including staff education, in-services, and technical troubleshooting.
  • Develop and maintain in-depth knowledge of assigned accounts and customers, including competitor activity.
  • Conduct evaluations and develop sales strategies for capital equipment opportunities within accounts.
  • Collect and study information about new and existing products and monitor competitor sales, prices, and products.
  • Provide feedback to providers in and outside the operating room on directions for use of implantable devices.
  • Attend trade shows and conferences to discuss new product developments with sales representatives and clients.
  • Use clinical expertise to identify customer training and in-service needs to increase customer use, comfort, and understanding of Abbott Chronic Pain Therapies.
  • Comply with U.S. Food and Drug Administration regulations, other regulatory requirements, company policies, operating procedures, processes, and task assignments.
  • Provide sales support, clinical in-services, training, and guidance to current or potential customers.
  • Maintain positive and cooperative communications and collaboration with employees, customers, contractors, and vendors at all levels.
  • Travel 25% within the assigned region and/or outside the assigned region.
  • Perform other related duties and responsibilities as assigned.
Desired Qualifications
  • Patient interaction experience in a healthcare-related environment, such as physical therapy, medical product sales, registered nurse, or licensed practical nurse.
  • Experience working in a broader enterprise or cross-division business unit model.
  • One to three years of experience with Abbott, a similar spinal cord stimulation setting, or another implantable medical device company.

About the company

Abbott develops and sells medical technologies and health solutions across cardiovascular care, diabetes management, diagnostics, nutrition, and neuromodulation. Cardiovascular devices help manage heart health; diabetes products enable glucose monitoring; diagnostic tests provide timely results; nutrition products support health; neuromodulation therapies target the nervous system to relieve pain or aid movement. It differentiates itself with a broad, integrated portfolio and a focus on accessibility and affordability of technologies worldwide. Its goal is to improve global health and well-being by delivering life-changing technologies that are accessible and affordable.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to Abbott

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 30, 2026 FDA approval lets CardioMEMS patients view pressure readings directly.
  • Abbott launched SimpleScreen CRC on September 30, 2026, widening oncology screening distribution.
  • August 2026 Libre Duo authorization created the first dual glucose-ketone wearable category.

What critics are saying

  • Abbott took $20.0 billion of debt for Exact Sciences, squeezing flexibility through 2027.
  • September 2026 formula settlement cost $385 million and reopened trust damage from 2022.
  • Dexcom and Stelo pressure CGM pricing while China core laboratory sales decline mid-single digits.

What makes Abbott unique

  • Abbott pairs CardioMEMS heart-failure monitoring with patient-facing smartphone workflow, September 2026.
  • March 2026 Exact Sciences made Abbott a scaled oncology diagnostics platform overnight.
  • FreeStyle Libre 3 Plus still anchors Abbott with 15-day wear and broad pump connectivity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Professional Development Budget

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

↑ 7%

1 year growth

↑ 7%

2 year growth

↑ 17%
PR Newswire
Oct 5th, 2026
Abbott wins FDA approval for CardioMEMS app showing heart failure patients their pressure readings

Abbott has received FDA approval for updates to its CardioMEMS HF System that enable new patient-facing capabilities through the CardioGuide HF App. For the first time, US patients with the implanted heart failure monitoring device can view their pulmonary artery pressure readings directly on their smartphones. The system measures pressure of blood flowing from the heart to the lungs, which can rise weeks before patients experience heart failure symptoms. The new capabilities also include Dynamic Treatment Plan software, allowing clinicians to send personalised medication adjustment instructions directly to patients through the app. The CardioMEMS HF System has been shown to reduce heart failure hospitalisations and mortality risk. Abbott plans to make the CardioGuide HF App and Dynamic Treatment Plan available later this year, helping patients take a more active role in managing their condition between doctor visits.

Emirates 24/7
Oct 4th, 2026
Dubai to host Concordia Horizon Summit in Middle East first.

Dubai to host Concordia Horizon Summit in Middle East first. Under the patronage of Maktoum bin Mohammed, the summit will bring together government leaders, business executives and decision-makers to advance public-private partnerships and economic cooperation His Highness Sheikh Maktoum bin Mohammed bin Rashid Al Maktoum, First Deputy Ruler of Dubai, Deputy Prime Minister and Minister of Finance, has announced that Dubai will host the Concordia Horizon Summit next May, bringing together executive leaders and decision-makers to explore opportunities for cooperation in public-private partnerships. Text Size: Dubai: Under the patronage of His Highness Sheikh Maktoum bin Mohammed bin Rashid Al Maktoum, First Deputy Ruler of Dubai, Deputy Prime Minister and Minister of Finance, Dubai will host the Concordia Horizon Summit for the first time in the Middle East in May 2027. The summit will bring together government leaders, business executives and decision-makers to discuss global challenges, explore areas of cooperation and accelerate public-private partnerships. The event will also feature the announcement of economic and development initiatives aimed at strengthening Dubai's position as a global centre for business and investment. Dubai's selection as the host city was announced during the Concordia Annual Summit in New York, held alongside the United Nations General Assembly in September 2026. Organised in collaboration with the Department of Finance for the Government of Dubai, the summit aims to reinforce Dubai's role as a global platform for leaders, experts and investors, while promoting opportunities and initiatives that support economic and investment cooperation across the Middle East. The Concordia Horizon Summit forms part of the international events organised by Concordia, a US-based non-profit organisation established in 2011 to bring together leaders from different sectors and foster strategic partnerships. The Dubai edition is expected to feature major announcements and partnerships, with a focus on translating discussions into investment opportunities and collaborative ventures across the Middle East and beyond. Fostering partnerships. His Excellency Abdulrahman Saleh Al Saleh, Director General of the Department of Finance for the Government of Dubai, said: "Dubai firmly believes that shaping the future begins with bringing intellectuals, experts and decision makers together around a shared vision, and translating that alignment into concrete steps that advance economies and enhance their future readiness." He added: "Hosting the Concordia Horizon Summit reflects international confidence in Dubai as an attractive destination for business and investment, as well as its capacity to convene key economic stakeholders around high-value, scalable opportunities." According to Al Saleh, the summit will provide a platform to anticipate trends shaping the global economy, leverage the expertise of participants and open new avenues for cooperation that support value-added initiatives and projects. Rodney Ferguson, CEO of Concordia, said: "Concordia and its global community are excited to be hosting our first Horizon Summit in the Middle East and the opportunities it will give our members to engage in critical discussions." He added: "We see clear alignment with Dubai's position as a global crossroads for innovation, investment, and economic growth, and Concordia's ability to bring voices from countless sectors into the same room." High-impact initiatives. The significance of Concordia's platform has been demonstrated through initiatives launched during previous summits. These include Prosper Africa, a financing framework designed to mobilise more than $800 million in private investment for infrastructure and climate adaptation projects in Africa through public-private partnerships, and Project Fury, an initiative by IDE Global aimed at empowering one million female entrepreneurs and improving the livelihoods of 100 million people through entrepreneurship programmes. At the 2024 Concordia Annual Summit, African Parks announced a $1 billion initiative to expand conservation efforts across Africa and manage 30 protected areas by 2030. The summit also saw Abbott Laboratories and Seed Global Health announce plans to establish a Centre of Excellence for Maternal Health in Malawi, focusing on clinical training and healthcare infrastructure. The Concordia Horizon Summit in Dubai is expected to provide a platform for public and private sector leaders to identify new opportunities for cooperation, advance investment initiatives and develop partnerships capable of delivering long-term economic and social impact. Further details about the summit's programme, participants and focus areas will be announced in the coming months.

Business Insider
Oct 2nd, 2026
RBC Capital sticks to its Buy rating for Abbott Laboratories (ABT).

RBC Capital sticks to its Buy rating for Abbott Laboratories (ABT). Oct. 2, 2026, 09:46 PM RBC Capital analyst Kendall Au maintained a Buy rating on Abbott Laboratories on October 1 and set a price target of $130.00. The company's shares closed yesterday at $96.69. Au covers the Healthcare sector, focusing on stocks such as Becton Dickinson, GE Healthcare Technologies Inc, and Boston Scientific. According to TipRanks, Au has an average return of -3.6% and a 22.22% success rate on recommended stocks. Currently, the analyst consensus on Abbott Laboratories is a Strong Buy with an average price target of $124.83, a 29.10% upside from current levels. In a report released yesterday, Rothschild & Co Redburn also upgraded the stock to a Buy with a $127.00 price target. Based on Abbott Laboratories' latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $12.59 billion and a net profit of $928 million. In comparison, last year the company earned a revenue of $11.14 billion and had a net profit of $1.78 billion Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABT in relation to earlier this year. Last month, JOHN A. JR. MCCOY, the VP & Controller of ABT sold 79.00 shares for a total of $8,696.30. Read More on ABT:

WBIW
Oct 1st, 2026
Bloomington Community Farmers' Market kicks off October with annual apple tasting and new hours.

Bloomington Community Farmers' Market kicks off October with annual apple tasting and new hours. October 1, 2026 BLOOMINGTON - As autumn settles into Southern Indiana, the Bloomington Community Farmers' Market is rolling out new seasonal hours alongside one of its most anticipated fall events. Starting this Saturday, October 3, the Market will operate under its October schedule, welcoming visitors from 9:00 a.m. to 12:30 p.m. at Showers Common (401 N. Morton St., next to City Hall). Taste over 15 apple & pear varieties this Saturday. Have you ever wondered how a Winter Banana compares to an Arkansas Black, or if a Mutsu is sweeter than a Gold Rush? Local marketgoers will have the chance to find out during the annual Apple Tasting on Fernandez Plaza. Running from 9:00 a.m. until 12:00 p.m. (or while supplies last), the free event invites visitors to sample more than 15 locally grown apple and pear varieties side by side. From crisp, tart options perfect for baking to sweet, juicy varieties made for snacking, the lineup features familiar staples as well as rare heirloom fruit seldom found in standard grocery stores. Featured varieties. * Apples: Arkansas Black, Blushing Gold, Brastar, Crimson Crisp, Galarina, Gold Rush, Golden Delicious, Granny Smith, Mutsu, Querina, Rhode Island Greening, September Wonder, Stayman Winesap, Winecrisp, and Winter Banana. * Pears: Asian Pear. Specialty treats including Autumn Apple Cookies and Spiced Apple Kombucha will also be available, and many of the featured fruit varieties can be purchased directly from vendor booths. No registration is required to attend. Live music & community events. Saturday's market features a double-header of live entertainment on the BCFM Circle Stage, alongside a chance to support a regional community challenge: * 9:15 a.m. & 11:30 a.m. - Tom "Guitar Tom" Harlan: The local singer-songwriter brings his signature mix of Old Time, Country, Bluegrass, Blues, and Rock across two performance sets. * 10:30 a.m. - 11:15 a.m. - Bloomington Peace Choir: This inclusive community choir performs a set featuring American folk, South African freedom songs, and music centered on themes of peace. * 9:00 a.m. - 12:00 p.m. - Mobile Blood Drive: In partnership with the Abbott and Big Ten WBIW Give Blood Challenge, Indiana University is calling on Hoosiers to donate blood. The Versiti bloodmobile will be parked along Morton Street. Advance spots can be reserved by contacting Katelyn at [email protected]. What's in Season at the Market. Beyond the apple tasting, vendor stalls will be packed with peak autumn produce, artisanal products, and value-added goods: Note: Vendor booth assignments are subject to change. Visitors seeking specific vendors can check in at the BCFM Information Booth. Season updates & Customer Survey. The Tuesday Market has officially wrapped up for the 2026 season. Market organizers thank all weekday shoppers for their support and look forward to welcoming everyone back for the 2027 season. Have Your Say: BCFM is inviting shoppers to complete its online Customer Survey to share feedback and suggestions for future markets. Participants will be entered into a drawing to win a free Market tote bag and a $5 Market gift certificate.

Boone Newspapers, Inc.
Oct 1st, 2026
Mississippi to receive more than $770,000 in settlement in national baby formula scandal.

Mississippi to receive more than $770,000 in settlement in national baby formula scandal. Published 5:37 am Thursday, October 1, 2026 | Getting your Trinity Audio player ready... | Mississippi will receive more than $770,000 in restitution after reaching a nationwide settlement with medical technology giant Abbott Laboratories over contaminated infant formula, Attorney General Lynn Fitch announced Wednesday. Mississippi joined 39 other states and the federal government in the $384.2 million agreement, which resolves allegations that Abbott manufactured and sold infant formula and nutritional products to government health programs that failed to meet state and federal safety standards. Under the terms of the settlement, Abbott will pay $348.7 million to the United States and $35.5 million to states to cover Medicaid-related claims. "Parents should be able to trust that the infant formula they feed their babies is safe, but Abbott betrayed that trust," AG Fitch said in a statement. "My office is dedicated to protecting the integrity of the Medicaid program and ensuring that Mississippians receive the necessities that their families rely on. This settlement holds Abbott accountable for knowingly manufacturing formula in substandard conditions and defrauding taxpayers." State and federal prosecutors alleged that Abbott knowingly used taxpayer funds to produce infant formula in unsanitary environments that put products at risk of microorganism contamination, compromising safety and quality. Furthermore, regulators alleged Abbott failed to disclose internal test results showing microorganism contamination when requested by the U.S. Food and Drug Administration (FDA) during 2019 and 2022 inspections at its Sturgis, Michigan facility. The settlement resolves the claims against Abbott, ensuring financial restitution for Mississippi taxpayers and Medicaid programs affected by the substandard manufacturing practices.